TSLA
Tesla
-- 424.770 NVDA
NVIDIA
-- 139.310 PLTR
Palantir
-- 72.510 SMCI
Super Micro Computer
-- 38.290 RGTI
Rigetti Computing
-- 7.3800 
NEWS
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection –
– An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in MDD; results from the interim analysis are expected in the first quarter of 2025, followed by topline data from the complete study sample in the first half of 2025 –
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the 63rd annual meeting of the American College of Neuropsychopharmacology (ACNP), in Phoenix, Arizona, held December 8-11, 2024.
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection –
– An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in MDD; results from the interim analysis are expected in the first quarter of 2025, followed by topline data from the complete study sample in the first half of 2025 –
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the 63rd annual meeting of the American College of Neuropsychopharmacology (ACNP), in Phoenix, Arizona, held December 8-11, 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment